FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281750952> ?p ?o ?g. }

• W4281750952 abstract "Background Due to the pandemic emergency caused by COVID-19, many countries were forced to apply a variety of measures such as quarantine and full national lockdown in order to contain the contagion. Medication adherence to chronic diseases may have been negatively influenced by restrictions due to the COVID-19 pandemic. The purpose of this study is to investigate adherence to urological therapies of patients with lower urinary tract symptoms (LUTSs) secondary to benign prostatic hyperplasia (BPH) during the COVID-19 lockdown period. Methods In this cohort study, we included a total of 151 male patients who were prescribed medications for LUTSs/benign prostatic enlargement (BPE) between January 2019 and December 2020. The prescriptive data of the following medications were collected: alpha-blockers (AB), 5-alpha reductase inhibitors (5-ARIs), 5-phosphodiesterase inhibitors (PDE5-i), antimuscarinics, and phytotherapy (i.e., Serenoa repens ). According to adherence or discontinuation of therapy, patients were divided into two groups: those who took their medications for a minimum of 6 months during the index period were considered in the “Medication adherence group” and those whose treatment was considered “discontinued” if it was interrupted for a 1-month period. Results Overall, the median age was 69.0 (interquartile range [IQR]: 63.0–74.0), the median International Prostate Symptom Score (IPSS) before the lockdown was 15.0 (IQR: 11.0–18.0), and the median IPSS–quality of life (IPSS-QoL) before the lockdown was 2.0 (IQR: 2.0–3.0). During the lockdown, 19 patients (12.58%) stopped taking their medications due to the pandemic situation: six (31.58%) stopped phytotherapy, two stopped AB+phytotherapy (10.53%), five stopped AB (26.32%), three stopped 5-ARIs (15.79%), one stopped antimuscarinics (5.26%), and two stopped other combination therapies (p &lt; 0.01). Among the patients who stopped therapy, five (26.31%) reported the presence of worsening symptoms (score ≥ 3), while 14 (73.69%) reported the absence of worsening symptoms (score &lt; 3). During the lockdown, five (3.31%) patients required hospitalization: three (1.99%) for acute urinary retention and two (1.32%) for urinary tract infection. Conclusions The rate of medication adherence for LUTSs/BPE during COVID-19 was 86.75%, but 13.25% of the patients had their treatments interrupted due to the pandemic situation. This rate determined a slight increase in symptoms with a potential impact on hospitalization. These results should be taken into account in order to develop adequate strategies in telehealth to maintain medication adherence for chronic diseases." @default.
• W4281750952 created "2022-06-13" @default.
• W4281750952 creator A5003872884 @default.
• W4281750952 creator A5016304963 @default.
• W4281750952 creator A5035549790 @default.
• W4281750952 creator A5037689340 @default.
• W4281750952 creator A5045062499 @default.
• W4281750952 creator A5046567234 @default.
• W4281750952 creator A5047333921 @default.
• W4281750952 creator A5048032405 @default.
• W4281750952 creator A5048499448 @default.
• W4281750952 creator A5059516379 @default.
• W4281750952 creator A5060706639 @default.
• W4281750952 creator A5064245222 @default.
• W4281750952 creator A5065095466 @default.
• W4281750952 creator A5070094301 @default.
• W4281750952 creator A5080149035 @default.
• W4281750952 creator A5081040806 @default.
• W4281750952 creator A5087758705 @default.
• W4281750952 creator A5089795540 @default.
• W4281750952 date "2022-06-06" @default.
• W4281750952 modified "2023-10-14" @default.
• W4281750952 title "Adherence to Urological Therapies for Lower Urinary Tract Symptoms Due to Benign Prostatic Enlargement During COVID-19 Lockdown" @default.
• W4281750952 cites W1968860914 @default.
• W4281750952 cites W2005179743 @default.
• W4281750952 cites W2009604837 @default.
• W4281750952 cites W3001118548 @default.
• W4281750952 cites W3012577433 @default.
• W4281750952 cites W3012600720 @default.
• W4281750952 cites W3012813927 @default.
• W4281750952 cites W3015195424 @default.
• W4281750952 cites W3019631904 @default.
• W4281750952 cites W3040398209 @default.
• W4281750952 cites W3127420938 @default.
• W4281750952 cites W3139810373 @default.
• W4281750952 cites W3214660538 @default.
• W4281750952 cites W4205614710 @default.
• W4281750952 cites W4251855550 @default.
• W4281750952 doi "https://doi.org/10.3389/fruro.2022.925575" @default.
• W4281750952 hasPublicationYear "2022" @default.
• W4281750952 type Work @default.
• W4281750952 citedByCount "0" @default.
• W4281750952 crossrefType "journal-article" @default.
• W4281750952 hasAuthorship W4281750952A5003872884 @default.
• W4281750952 hasAuthorship W4281750952A5016304963 @default.
• W4281750952 hasAuthorship W4281750952A5035549790 @default.
• W4281750952 hasAuthorship W4281750952A5037689340 @default.
• W4281750952 hasAuthorship W4281750952A5045062499 @default.
• W4281750952 hasAuthorship W4281750952A5046567234 @default.
• W4281750952 hasAuthorship W4281750952A5047333921 @default.
• W4281750952 hasAuthorship W4281750952A5048032405 @default.
• W4281750952 hasAuthorship W4281750952A5048499448 @default.
• W4281750952 hasAuthorship W4281750952A5059516379 @default.
• W4281750952 hasAuthorship W4281750952A5060706639 @default.
• W4281750952 hasAuthorship W4281750952A5064245222 @default.
• W4281750952 hasAuthorship W4281750952A5065095466 @default.
• W4281750952 hasAuthorship W4281750952A5070094301 @default.
• W4281750952 hasAuthorship W4281750952A5080149035 @default.
• W4281750952 hasAuthorship W4281750952A5081040806 @default.
• W4281750952 hasAuthorship W4281750952A5087758705 @default.
• W4281750952 hasAuthorship W4281750952A5089795540 @default.
• W4281750952 hasBestOaLocation W42817509521 @default.
• W4281750952 hasConcept C119060515 @default.
• W4281750952 hasConcept C121608353 @default.
• W4281750952 hasConcept C126322002 @default.
• W4281750952 hasConcept C126894567 @default.
• W4281750952 hasConcept C2776235491 @default.
• W4281750952 hasConcept C2776547966 @default.
• W4281750952 hasConcept C2778715236 @default.
• W4281750952 hasConcept C2779134260 @default.
• W4281750952 hasConcept C2779478474 @default.
• W4281750952 hasConcept C2779929075 @default.
• W4281750952 hasConcept C2780816001 @default.
• W4281750952 hasConcept C3008058167 @default.
• W4281750952 hasConcept C524204448 @default.
• W4281750952 hasConcept C71924100 @default.
• W4281750952 hasConcept C77411442 @default.
• W4281750952 hasConceptScore W4281750952C119060515 @default.
• W4281750952 hasConceptScore W4281750952C121608353 @default.
• W4281750952 hasConceptScore W4281750952C126322002 @default.
• W4281750952 hasConceptScore W4281750952C126894567 @default.
• W4281750952 hasConceptScore W4281750952C2776235491 @default.
• W4281750952 hasConceptScore W4281750952C2776547966 @default.
• W4281750952 hasConceptScore W4281750952C2778715236 @default.
• W4281750952 hasConceptScore W4281750952C2779134260 @default.
• W4281750952 hasConceptScore W4281750952C2779478474 @default.
• W4281750952 hasConceptScore W4281750952C2779929075 @default.
• W4281750952 hasConceptScore W4281750952C2780816001 @default.
• W4281750952 hasConceptScore W4281750952C3008058167 @default.
• W4281750952 hasConceptScore W4281750952C524204448 @default.
• W4281750952 hasConceptScore W4281750952C71924100 @default.
• W4281750952 hasConceptScore W4281750952C77411442 @default.
• W4281750952 hasLocation W42817509521 @default.
• W4281750952 hasOpenAccess W4281750952 @default.
• W4281750952 hasPrimaryLocation W42817509521 @default.
• W4281750952 hasRelatedWork W1559582992 @default.
• W4281750952 hasRelatedWork W2016054225 @default.
• W4281750952 hasRelatedWork W2037716159 @default.
• W4281750952 hasRelatedWork W2051497077 @default.
• W4281750952 hasRelatedWork W2074093603 @default.

• next